Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. (000766.SZ) has released its interim results for the first half of 2026, revealing a significant decline in profitability amid challenging market conditions.
During the reporting period, the company generated total operating revenue of RMB 557 million, marking a year-on-year decrease of 14.28%. Net profit attributable to shareholders of the listed company stood at RMB 7.1046 million, plummeting 57.72% compared to the same period last year. After excluding non-recurring gains and losses, net profit attributable to shareholders reached RMB 6.1171 million, down 57.54% year-on-year. Basic earnings per share came in at RMB 0.0074.
In the first half of the year, the company faced deepening pharmaceutical industry policies and shifting market dynamics. Under the guidance of the board of directors and with the persistent efforts of all employees, Tonghua Golden-Horse adhered to an innovation-driven strategy, accelerating the research and industrialization of key products. The company steadily advanced lean management practices, continuously optimized its marketing system and channel layout, and strived to maintain stable business operations and performance despite the headwinds.
Comments